India Drug Research Support Program Given Quiet Death
This article was originally published in PharmAsia News
India's seven-year program aimed at supporting pharmaceutical research has been allowed to die. An official with the Department of Science and Technology confirmed the fund has been dissolved, replaced by the general funds of the ministry. Begun in the 2000-2001 budget, the fund became controversial from the beginning and encountered jurisdictional problems between the DST and the Chemicals and Fertilizers Ministry. Ending up in the DST, only the interest from the fund became available to the industry to support the expensive drug-development process. An industry representative also cited a problem with company reluctance to share research data with a government agency. (Click here for more
You may also be interested in...
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.
AstraZeneca's research head admits that the half dose approach was a lucky mistake – but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.